Product Details

Canada scrambles to reboot sagging clinical trials market

Canada has seen a precipitous drop in research and has the newly earned distinction of being the world’s biggest loser of investigative sites and enrolled patients in a benchmark comparison study, a downward trend particularly startling for a country that only six years ago was considered the world leader in recruitment reliability. A confluence of factors has made Canada a slow and expensive location for trials, and rebooting the market will require...

Supply chain partnerships morphing into strategic alliances

As happened with CROs a few years ago, supply chain relationships are moving from a tactical, single-trial model toward strategic alliances with a smaller number of key vendors. And both big pharma and biotech are embracing the idea in the name of efficiency and...

Eye On Eli Lilly

Eli Lilly has a history of innovation beginning in 1876 and is now the tenth largest pharmaceutical company worldwide. Its global presence includes clinical research performed in more than 50 countries. Lilly’s R&D focus is to generate potential biotech solutions for a wide range of diseases, and to pursue personalized medicines...

• CRAs must form positive relationships
• Increasing the effectiveness of novel imaging in trials
• Regulatory Update
• Month in Review
• CRO Industry Update
• TrialWatch
• New Study Launches